Gas Biopsy of Pleural Effusion to Diagnose Lung Cancer by Mass Spectrometry

Abstract

Lung cancer (LC) is a leading cause of cancer mortality worldwide, frequently complicated by malignant pleural effusion (MPE). This study aimed to investigate volatile organic compounds (VOCs) in pleural effusion to identify metabolic biomarkers for LC. A total of 107 LC-related MPE and 112 benign pleural effusion (BPE) patients were enrolled and divided into discovery (MPE: n = 75; BPE: n = 78) and validation (MPE: n = 32; BPE: n = 34) cohorts. Paired tumor and adjacent nontumor tissues from 14 LC patients formed an independent cohort. Differential VOCs were identified using criteria of q < 0.05, |log₂ fold change| > 1, and VIP > 1.5 in both the pleural effusion discovery cohort and the tissue cohort. Hexanal was identified as the only LC-associated VOC present across both compartments. In the validation cohort, hexanal demonstrated strong diagnostic performance in distinguishing MPE from BPE (AUC = 0.8339; sensitivity 75.00%; specificity 65.71%). Single-cell analysis indicated that hexanal accumulation is linked to fatty acid metabolism reprogramming. This study supports pleural effusion-based gas biopsy as a promising LC diagnostic approach.

Keywords

gas biopsy / lung cancer / pleural effusion / tumor tissue / volatile organic compounds

References

[1] R. L. Siegel, T. B. Kratzer, A. N. Giaquinto, H. Sung, and A. Jemal, “Cancer Statistics, 2025,” CA: A Cancer Journal for Clinicians 75, no. 1 (2025): 10–45.

[2] J. Huang, Y. Deng, M. S. Tin, et al., “Distribution, Risk Factors, and Temporal Trends for Lung Cancer Incidence and Mortality: A Global Analysis,” Chest 161, no. 4 (2022): 1101–1111.

[3] A. Leiter, R. R. Veluswamy, and J. P. Wisnivesky, “The Global Burden of Lung Cancer: Current Status and Future Trends,” Nature Reviews Clinical Oncology 20, no. 9 (2023): 624–639.

[4] F. Gouzerh, J. Bessière, B. Ujvari, et al., “Odors and Cancer: Current Status and Future Directions,” Biochim Biophys Acta Rev Cancer 1877, no. 1 (2022): 188644.

[5] M. Leemans, R. P. Bau, V. Cuzuel, E. Audureau, and I. Fromantin, “Volatile Organic Compounds Analysis as a Potential Novel Screening Tool for Breast Cancer: A Systematic Review,” Biomark Insights 17 (2022): 885600091.

[6] J. Chung, S. Akter, S. Han, et al., “Diagnosis by Volatile Organic Compounds in Exhaled Breath From Patients With Gastric and Colorectal Cancers,” International Journal of Molecular Sciences 24, no. 1 (2022): 129.

[7] S. R. Sutaria, S. S. Gori, J. D. Morris, et al., “Lipid Peroxidation Produces a Diverse Mixture of Saturated and Unsaturated Aldehydes in Exhaled Breath That Can Serve as Biomarkers of Lung Cancer—A Review,” Metabolites 12, no. 6 (2022): 561.

[8] F. Choueiry, A. Barham, and J. Zhu, “Analyses of Lung Cancer-derived Volatiles in Exhaled Breath and in Vitro Models,” Exp Biol Med (Maywood) 247, no. 13 (2022): 1179–1190.

[9] X. Fan, R. Zhong, H. Liang, et al., “Exhaled VOC Detection in Lung Cancer Screening: A Comprehensive Meta-analysis,” BMC Cancer 24, no. 1 (2024): 775.

[10] F. Schmidt, D. Kohlbrenner, S. Malesevic, et al., “Mapping the Landscape of Lung Cancer Breath Analysis: A Scoping Review (ELCABA),” Lung Cancer 175 (2023): 131–140.

[11] P. C. Kulandaisamy, S. Kulandaisamy, D. Kramer, and C. Mcgrath, “Malignant Pleural Effusions-A Review of Current Guidelines and Practices,” Journal of Clinical Medicine 10, no. 23 (2021): 5535.

[12] K. Skok, G. Hladnik, A. Grm, and A. Crnjac, “Malignant Pleural Effusion and Its Current Management: A Review,” Medicina (Kaunas) 55, no. 8 (2019): 490.

[13] R. Orlandi, A. Cara, and E. M. Cassina, “Malignant Pleural Effusion: Diagnosis and Treatment-Up-to-Date Perspective,” Curr Oncol 31, no. 11 (2024): 6867–6878.

[14] Y. Niu and Q. Zhou, “Th17 cells and Their Related Cytokines: Vital Players in Progression of Malignant Pleural Effusion,” Cellular and Molecular Life Sciences 79, no. 4 (2022): 194.

[15] K. K. Pasikanti, P. C. Ho, and E. C. Chan, “Gas Chromatography/Mass Spectrometry in Metabolic Profiling of Biological Fluids,” Journal of Chromatography B, Analytical Technologies in the Biomedical and Life Sciences 871, no. 2 (2008): 202–211.

[16] H. Liu, C. Li, H. Wang, et al., “Characterization of Volatile Organic Metabolites in Lung Cancer Pleural Effusions by SPME–GC/MS Combined With an Untargeted Metabolomic Method,” Chromatographia 77, no. 19-20 (2014): 1379–1386.

[17] K. Chen, S. Tsai, X. Zhang, C. Zeng, and H. Yang, “The Investigation of the Volatile Metabolites of Lung Cancer From the Microenvironment of Malignant Pleural Effusion,” Scientific Reports 11, no. 1 (2021): 13585.

[18] N. H. Mari, E. Derveaux, K. Vanhove, et al., “Changes in Metabolism as a Diagnostic Tool for Lung Cancer: Systematic Review,” Metabolites 12, no. 6 (2022): 545.

[19] K. B. Lee, L. Ang, W. Yau, and W. J. Seow, “Association Between Metabolites and the Risk of Lung Cancer: A Systematic Literature Review and Meta-Analysis of Observational Studies,” Metabolites 10, no. 9 (2020): 362.

[20] L. Ferreiro, J. Suárez-Antelo, J. M. Álvarez-Dobaño, et al., “Malignant Pleural Effusion: Diagnosis and Management,” Canadian Respiratory Journal 2020 (2020): 1–11.

[21] M. A. Floss, T. Fink, F. Maurer, et al., “Exhaled Aldehydes as Biomarkers for Lung Diseases: A Narrative Review,” Molecules 27, no. 16 (2022): 5258.

[22] M. Phillips, K. Gleeson, J. M. Hughes, et al., “Volatile Organic Compounds in Breath as Markers of Lung Cancer: A Cross-sectional Study,” Lancet 353, no. 9168 (1999): 1930–1933.

[23] C. Deng, X. Zhang, and N. Li, “Investigation of Volatile Biomarkers in Lung Cancer Blood Using Solid-phase Microextraction and Capillary Gas Chromatography-mass Spectrometry,” Journal of Chromatography B, Analytical Technologies in the Biomedical and Life Sciences 808, no. 2 (2004): 269–277.

[24] R. Guadagni, N. Miraglia, A. Simonelli, et al., “Solid-phase Microextraction–gas Chromatography–mass Spectrometry Method Validation for the Determination of Endogenous Substances: Urinary Hexanal and Heptanal as Lung Tumor Biomarkers,” Analytica Chimica Acta 701, no. 1 (2011): 29–36.

[25] F. Bianchi, N. Riboni, P. Carbognani, et al., “Solid-phase Microextraction Coupled to Gas Chromatography–mass Spectrometry Followed by Multivariate Data Analysis for the Identification of Volatile Organic Compounds as Possible Biomarkers in Lung Cancer Tissues,” Journal of Pharmaceutical and Biomedical Analysis 146 (2017): 329–333.

[26] K. Wu, A. E. El Zowalaty, V. I. Sayin, and T. Papagiannakopoulos, “The Pleiotropic Functions of Reactive Oxygen Species in Cancer,” Nat Cancer 5, no. 3 (2024): 384–399.

[27] N. Gupta, N. S. Abd El-Gawaad, L. O. Mallasiy, S. Alghamdi, and V. K. Yadav, “Hydrogen: An Advanced and Safest Gas Option for Cancer Treatment,” Med Gas Res 15, no. 2 (2025): 191–192.

[28] S. Y. Lee, N. Park, E. Jeong, et al., “Comparison of GC/MS and LC/MS Methods for the Analysis of Propofol and Its Metabolites in Urine,” Journal of Chromatography B, Analytical Technologies in the Biomedical and Life Sciences 900 (2012): 1–10.

[29] G. Gregis, S. Schaefer, J. Sanchez, et al., “Characterization of Materials Toward Toluene Traces Detection for Air Quality Monitoring and Lung Cancer Diagnosis,” Materials Chemistry and Physics 192 (2017): 374–382.

[30] A. Ulanowska, T. Kowalkowski, E. Trawinska, and B. Buszewski, “The Application of Statistical Methods Using VOCs to Identify Patients With Lung Cancer,” Journal of Breath Research 5, no. 4 (2011): 046008.

[31] R. D. Riley, J. Ensor, K. Snell, et al., “Calculating the Sample Size Required for Developing a Clinical Prediction Model,” BMJ 368 (2020): m441.

[32] J. Zhou, D. Ge, Y. Liu, et al., “Developing Multiple Media Approach to Investigate Reproducible Characteristic VOCs of Lung Cancer Cells,” Analytical Chemistry 96, no. 52 (2024): 20398–20405.

[33] Y. Liu, D. Ge, J. Zhou, et al., “HS–SPME–GC–MS Untargeted Analysis of Normal Rat Organs Ex Vivo: Differential VOC Discrimination and Fingerprint VOC Identification,” Analytical Chemistry 95, no. 30 (2023): 11375–11382.

[34] D. Ge, J. Zhou, Y. Chu, et al., “Distinguish Oral-source VOCs and Control Their Potential Impact on Breath Biomarkers,” Anal Bioanal Chem 414, no. 6 (2022): 2275–2284.

[35] Y. Chu, D. Ge, J. Zhou, et al., “Controlling Glycolysis to Generate Characteristic Volatile Organic Compounds of Lung Cancer Cells,” Scientific Reports 14, no. 1 (2024): 16561.

[36] W. B. Dunn, D. Broadhurst, P. Begley, et al., “Procedures for Large-scale Metabolic Profiling of Serum and Plasma Using Gas Chromatography and Liquid Chromatography Coupled to Mass Spectrometry,” Nature Protocols 6, no. 7 (2011): 1060–1083.

[37] R. Tautenhahn, G. J. Patti, D. Rinehart, and G. Siuzdak, “XCMS Online: A Web-Based Platform to Process Untargeted Metabolomic Data,” Analytical Chemistry 84, no. 11 (2012): 5035–5039.

[38] D. Kessner, M. Chambers, R. Burke, D. Agus, and P. Mallick, “ProteoWizard: Open Source Software for Rapid Proteomics Tools Development,” Bioinformatics 24, no. 21 (2008): 2534–2536.

[39] E. M. Forsberg, T. Huan, D. Rinehart, et al., “Data Processing, Multi-omic Pathway Mapping, and Metabolite Activity Analysis Using XCMS Online,” Nature Protocols 13, no. 4 (2018): 633–651.

[40] X. Zheng, D. Ge, J. Zhou, et al., “Investigation of Characteristic Volatile Organic Compounds in Esophageal Cancer Organoids by Mass Spectrometry,” Analytical Chemistry 97, no. 33 (2025): 17962–17969.

[41] J. H. Winnike, X. Wei, K. J. Knagge, et al., “Comparison of GC-MS and GCxGC-MS in the Analysis of human Serum Samples for Biomarker Discovery,” Journal of Proteome Research 14, no. 4 (2015): 1810–1817.

[42] B. Mahieu, E. M. Qannari, and B. Jaillais, “Extension and Significance Testing of Variable Importance in Projection (VIP) Indices in Partial Least Squares Regression and Principal Components Analysis,” Chemometr Intell Lab Syst 242 (2023): 104986.

[43] D. Ge, X. Zou, Y. Chu, et al., “Analysis of Volatile Organic Compounds in Exhaled Breath After Radiotherapy,” J Zhejiang Univ Sci B 23, no. 2 (2022): 153–157.

[44] C. Cheng, W. Chen, H. Jin, and X. Chen, “A Review of Single-Cell RNA-Seq Annotation, Integration, and Cell-Cell Communication,” Cells 12, no. 15 (2023): 1970.

[45] Z. Tan, X. Chen, J. Zuo, et al., “Comprehensive Analysis of scRNA-Seq and Bulk RNA-Seq Reveals Dynamic Changes in the Tumor Immune Microenvironment of Bladder Cancer and Establishes a Prognostic Model,” Journal of translational medicine 21, no. 1 (2023): 223.

[46] J. Liang, R. Liang, K. Lei, et al., “Comparative Analysis of Single-cell Transcriptome Reveals Heterogeneity in the Tumor Microenvironment of Lung Adenocarcinoma and Brain Metastases,” Discov Oncol 14, no. 1 (2023): 174.

[47] D. Yu, S. Zhang, Z. Liu, et al., “Single-Cell RNA Sequencing Analysis of Gene Regulatory Network Changes in the Development of Lung Adenocarcinoma,” Biomolecules 13, no. 4 (2023): 671.

[48] Z. Chen, M. Zhao, M. Li, et al., “Identification of Differentially Expressed Genes in Lung Adenocarcinoma Cells Using Single-cell RNA Sequencing Not Detected Using Traditional RNA Sequencing and Microarray,” Laboratory Investigation 100, no. 10 (2020): 1318–1329.

RIGHTS & PERMISSIONS

2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.